Aurobindo Pharma receives final approval for Lamotrigine Tablets from USFDA

5th November 2009

Aurobindo Pharma Limited is pleased to announce that it has received the final approval for Lamotrigine Tablets (Chewable, Dispersible) 5mg and 25mg from the US Food & Drug Administration (USFDA).

Lamotrigine Tablets 5mg and 25mg is generic equivalent to Lamictal® CD Tablets 5mg and 25mg of GlaxoSmithKline. Lamotrigine tablet falls under the CNS (Central Nervous System) segment and is indicated as adjunctive therapy for partial seizures and generalized seizures of Lennox - Gastaut syndrome in patients aged 2 years and older, and for conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing antiepileptic drug. The product would be launched soon.

Aurobindo now has a total of 107 ANDA approvals (78 Final approvals and 29 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterological, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com